Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells.
Monocyte-derived dendritic cells (moDC) have been widely used in cancer immunotherapy but show significant donor-to-donor variability and low capacity for the cross-presentation of tumour-associated antigens (TAA) to CD8(+) T cells, greatly limiting the success of this approach. Given recent develop...
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Journal article |
| Lingua: | English |
| Pubblicazione: |
2012
|
| _version_ | 1826295307069030400 |
|---|---|
| author | Silk, K Silk, J Ichiryu, N Davies, T Nolan, K Leishman, A Carpenter, L Watt, S Cerundolo, V Fairchild, P |
| author_facet | Silk, K Silk, J Ichiryu, N Davies, T Nolan, K Leishman, A Carpenter, L Watt, S Cerundolo, V Fairchild, P |
| author_sort | Silk, K |
| collection | OXFORD |
| description | Monocyte-derived dendritic cells (moDC) have been widely used in cancer immunotherapy but show significant donor-to-donor variability and low capacity for the cross-presentation of tumour-associated antigens (TAA) to CD8(+) T cells, greatly limiting the success of this approach. Given recent developments in induced pluripotency and the relative ease with which induced pluripotent stem (iPS) cell lines may be generated from individuals, we have succeeded in differentiating dendritic cells (DC) from human leukocyte antigen (HLA)-A(*)0201(+) iPS cells (iPS cell-derived DC (ipDC)), using protocols compliant with their subsequent clinical application. Unlike moDC, a subset of ipDC was found to coexpress CD141 and XCR1 that have been shown previously to define the human equivalent of mouse CD8α(+) DC, in which the capacity for cross-presentation has been shown to reside. Accordingly, ipDC were able to cross-present the TAA, Melan A, to a CD8(+) T-cell clone and stimulate primary Melan A-specific responses among naïve T cells from an HLA-A(*)0201(+) donor. Given that CD141(+)XCR1(+) DC are present in peripheral blood in trace numbers that preclude their clinical application, the ability to generate a potentially unlimited source from iPS cells offers the possibility of harnessing their capacity for cross-priming of cytotoxic T lymphocytes for the induction of tumour-specific immune responses. |
| first_indexed | 2024-03-07T03:59:00Z |
| format | Journal article |
| id | oxford-uuid:c3ddb787-c2a5-4f11-beca-955ef7eb5c5c |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T03:59:00Z |
| publishDate | 2012 |
| record_format | dspace |
| spelling | oxford-uuid:c3ddb787-c2a5-4f11-beca-955ef7eb5c5c2022-03-27T06:19:38ZCross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:c3ddb787-c2a5-4f11-beca-955ef7eb5c5cEnglishSymplectic Elements at Oxford2012Silk, KSilk, JIchiryu, NDavies, TNolan, KLeishman, ACarpenter, LWatt, SCerundolo, VFairchild, PMonocyte-derived dendritic cells (moDC) have been widely used in cancer immunotherapy but show significant donor-to-donor variability and low capacity for the cross-presentation of tumour-associated antigens (TAA) to CD8(+) T cells, greatly limiting the success of this approach. Given recent developments in induced pluripotency and the relative ease with which induced pluripotent stem (iPS) cell lines may be generated from individuals, we have succeeded in differentiating dendritic cells (DC) from human leukocyte antigen (HLA)-A(*)0201(+) iPS cells (iPS cell-derived DC (ipDC)), using protocols compliant with their subsequent clinical application. Unlike moDC, a subset of ipDC was found to coexpress CD141 and XCR1 that have been shown previously to define the human equivalent of mouse CD8α(+) DC, in which the capacity for cross-presentation has been shown to reside. Accordingly, ipDC were able to cross-present the TAA, Melan A, to a CD8(+) T-cell clone and stimulate primary Melan A-specific responses among naïve T cells from an HLA-A(*)0201(+) donor. Given that CD141(+)XCR1(+) DC are present in peripheral blood in trace numbers that preclude their clinical application, the ability to generate a potentially unlimited source from iPS cells offers the possibility of harnessing their capacity for cross-priming of cytotoxic T lymphocytes for the induction of tumour-specific immune responses. |
| spellingShingle | Silk, K Silk, J Ichiryu, N Davies, T Nolan, K Leishman, A Carpenter, L Watt, S Cerundolo, V Fairchild, P Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. |
| title | Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. |
| title_full | Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. |
| title_fullStr | Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. |
| title_full_unstemmed | Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. |
| title_short | Cross-presentation of tumour antigens by human induced pluripotent stem cell-derived CD141(+)XCR1+ dendritic cells. |
| title_sort | cross presentation of tumour antigens by human induced pluripotent stem cell derived cd141 xcr1 dendritic cells |
| work_keys_str_mv | AT silkk crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT silkj crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT ichiryun crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT daviest crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT nolank crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT leishmana crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT carpenterl crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT watts crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT cerundolov crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells AT fairchildp crosspresentationoftumourantigensbyhumaninducedpluripotentstemcellderivedcd141xcr1dendriticcells |